Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Idiopathic Pulmory Fibrosis - Overview
Idiopathic Pulmory Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Idiopathic Pulmory Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Idiopathic Pulmory Fibrosis - Companies Involved in Therapeutics Development
Idiopathic Pulmory Fibrosis - Drug Profiles
Idiopathic Pulmory Fibrosis - Dormant Projects
Idiopathic Pulmory Fibrosis - Discontinued Products
Idiopathic Pulmory Fibrosis - Product Development Milestones
Featured News & Press Releases
Oct 05, 2022: Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn
Sep 06, 2022: NXP002 data to be presented at the 2022 European Respiratory Society Congress
Aug 17, 2022: Arrowhead files for regulatory clearance to initiate phase 1/2a study of ARO-MMP7 for idiopathic pulmory fibrosis
Aug 17, 2022: Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress
Aug 15, 2022: Bridge Biotherapeutics receives FDA authorization to proceed with phase 2 study of BBT-877
Aug 10, 2022: Nuformix : NXP002 successful completion of tolerability studies
Aug 03, 2022: Algernon Pharmaceuticals invited to present phase 2 IPF and chronic cough study data at 9th American Cough Conference
Aug 02, 2022: Elixiron Immunotherapeutics announces orphan drug desigtion granted to CSF-1R inhibitor, EI-1071 for the treatment of idiopathic pulmory fibrosis
Jul 28, 2022: Algernon Pharmaceuticals reports additiol positive data from its phase 2 study of Ifenprodil for IPF and chronic cough
Jul 20, 2022: Daewoong Pharmaceutical gets first Korean US FDA fast-track for new idiopathic pulmory fibrosis drug
Jul 11, 2022: Pliant reports positive data from Phase IIa idiopathic pulmory fibrosis trial
Jul 04, 2022: AD-214 program modified to maximise partnering options, extends cash runway
Jun 30, 2022: PureTech initiates late-stage clinical study of wholly-owned candidate LYT-100 (deupirfenidone) in IPF
Jun 27, 2022: Nuformix : NXP002 Update
Jun 24, 2022: Daewoong Pharmaceutical begins multitiol phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmory fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Idiopathic Pulmonary Fibrosis - Dormant Projects, 2022
Idiopathic Pulmonary Fibrosis - Discontinued Products, 2022